Clinical Trial

A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is an interventional, modular, open-label, multicenter study to primarily evaluate the safety and tolerability of AZD0120 in adult participants with multiple myeloma (MM).
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2025-07-10; most recent amendment 2026-07-10.
Trial Details
NCT Number NCT07073547
Lead Sponsor AstraZeneca
Conditions Multiple Myeloma
Enrollment 40 participants
Start Date 2025-07-31
Primary Completion 2028-05-26 (estimated)
Study Completion 2028-05-26 (estimated)
Updated on ClinicalTrials.gov 2026-07-13